| Serial Number | 85021908 |
| Word Mark | AMT. |
| Filing Date | Friday, April 23, 2010 |
| Status | 710 - CANCELLED - SECTION 8 |
| Status Date | Friday, October 19, 2018 |
| Registration Number | 4110829 |
| Registration Date | Tuesday, March 13, 2012 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, December 27, 2011 |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Description of Mark | The mark consists of "amt." surrounded by a solid circle. |
| Goods and Services | Nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cell transformed by viral vectors, gene therapy vectors and nucleic acid delivery vectors for other than medical and veterinary purposes; chemical reagents for scientific or research use, namely, nucleic acids and vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes |
| Goods and Services | Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and call therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders, single gene disorders and cancers; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers |
| Goods and Services | Laboratory research in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry; product development and consultancy in the field of biologics, pharmaceutics, medical science, chemistry and biochemistry |
| Goods and Services | Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation |
| Pseudo Mark | AMSTERDAM MOLECULAR THERAPEUTICS |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, October 19, 2018 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, October 19, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, October 19, 2018 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, October 19, 2018 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Amsterdam Molecular Therapeutics (AMT) IP B.V. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Amsterdam 1105BA NL |
| Party Name | Amsterdam Molecular Therapeutics (AMT) IP B.V. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Amsterdam 1105BA NL |
| Party Name | Amsterdam Molecular Therapeutics (AMT) IP B.V. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Amsterdam 1105BA NL |
| Event Date | Event Description |
| Friday, October 19, 2018 | CANCELLED SEC. 8 (6-YR) |
| Monday, March 13, 2017 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Tuesday, March 13, 2012 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, December 27, 2011 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 27, 2011 | PUBLISHED FOR OPPOSITION |
| Wednesday, December 7, 2011 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, November 22, 2011 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Monday, November 21, 2011 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, November 4, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, November 4, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, November 4, 2011 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 5, 2011 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 5, 2011 | NON-FINAL ACTION E-MAILED |
| Thursday, May 5, 2011 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 13, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 13, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 13, 2011 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, February 9, 2011 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, February 9, 2011 | NON-FINAL ACTION E-MAILED |
| Wednesday, February 9, 2011 | NON-FINAL ACTION WRITTEN |
| Tuesday, January 18, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 18, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 11, 2011 | ASSIGNED TO LIE |
| Monday, December 20, 2010 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, June 22, 2010 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, June 22, 2010 | NON-FINAL ACTION E-MAILED |
| Tuesday, June 22, 2010 | NON-FINAL ACTION WRITTEN |
| Tuesday, June 22, 2010 | ASSIGNED TO EXAMINER |
| Friday, April 30, 2010 | NOTICE OF DESIGN SEARCH CODE MAILED |
| Thursday, April 29, 2010 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, April 27, 2010 | NEW APPLICATION ENTERED IN TRAM |